Prognostic role of tumor size in T1 HER2-positive breast cancers treated with adjuvant trastuzumab.

Campiglio, M; Sandri, M; Sasso, M; Bianchi, F; Balsari, A; Ménard, S; Tagliabue, E

Campiglio, M; Sandri, M; Sasso, M; Bianchi, F; Balsari, A; Ménard, S; Tagliabue, E.

Affiliation

Campiglio M; Molecular Targeting Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.

Ann Oncol ; 25(5): 1073-4, 2014 May.

Article in En | MEDLINE | ID: mdl-24558025

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use; Antineoplastic Agents/therapeutic use; Breast Neoplasms/pathology; Receptor, ErbB-2/metabolism; Breast Neoplasms/metabolism; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Trastuzumab; Tumor Burden

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Receptor, ErbB-2 / Antibodies, Monoclonal, Humanized / Antineoplastic Agents Type of study: Prognostic_studies Limits: Female / Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2014 Type: Article

Fulltext

XML

PubMed Links

Search on Google